Clinical relevance of cyclooxygenase-2 and matrix metalloproteinases (MMP-2 and MT1-MMP) in human breast cancer tissue

Mohammad, Mohammad; Zeeneldin, Ahmed; Abd Elmageed, Zakaria; Khalil, Ebtsam; Mahdy, Said; Sharada, Hayat; Sharawy, Sabry; Abdel-Wahab, Abdel-Hady
July 2012
Molecular & Cellular Biochemistry;Jul2012, Vol. 366 Issue 1/2, p269
Academic Journal
Breast cancer (BC) is the most common neoplasm among women in most developed countries, including Egypt. Elevated levels of certain proteins in human BC are associated with unfavorable prognosis and progressive stages of the disease. The aim of our study was to evaluate the protein expression profile and prognostic significance of cyclooxygenase-2 (COX-2), matrix metalloproteinase-2 (MMP-2), MMP-9 and membrane type 1-MMP (MT1-MMP) and their interaction in operable BC patients. The protein expression of COX-2, MMP-2 and MT1-MMP were evaluated by western blot technique, whereas enzymatic activity of MMP-2 and MMP-9 was determined by zymography in 47 breast cancer patients as well as normal adjacent tissues. Also, the correlation between these proteins and age, tumor size, LN stage, TNM stage, estrogen receptor, progesterone receptor, disease-free survival, and overall survival (OS) has been investigated. As compared to adjacent normal tissues, COX-2, MMP-2 and MT1-MMP were over-expressed in 43, 64, and 60 % of tumor tissues, respectively. In the same pattern, the activity of MMP-2 (62 %) and MMP-9 (45 %) was elevated in BC tissues. Multivariate analysis showed a positive correlation between the protein expression of COX-2, MMP-2, and MT1-MMP and the activity of MMP-2 and MMP-9 in BC patients. However, the enzymatic activity showed no correlation with clinicopathological features. This study confirms the preclinical evidence that COX-2 increased the expression of MT1-MMP, which in turn activates MMP-2. The lack of correlation with clinicopathological features, OS or disease-free survival ascertains the complexity of tumor progression and metastasis with many pro- and counter regulatory factors.


Related Articles

  • Commentary: Can Circulating HER-2 Extracellular Domain Predict Response to Trastuzumab in HER-2--Negative Breast Cancer? Esteva, Francisco J. // Oncologist;Apr2008, Vol. 13 Issue 4, p370 

    The article examines the capability of human epidermal growth factor receptor 2 (HER-2) extracellular domain (ECD) enzyme to predict response of breast cancer patients to trastuzumab therapy. It states that HER-2 is a type I family of tyrosine kinase growth factor receptors whose structure...

  • Manual lymphatic drainage therapy in patients with breast cancer related lymphoedema. Martín, Marta López; Hernández, Miguel A.; Avendaño, Cristina; Rodríguez, Francisco; Martínez, Helena // BMC Cancer;2011, Vol. 11 Issue 1, p94 

    Background: Lymphoedema is a common and troublesome condition that develops following breast cancer treatment. The aim of this study is to analyze the effectiveness of Manual Lymphatic Drainage in the treatment of postmastectomy lymphoedema in order to reduce the volume of lymphoedema and...

  • Tissue levels of adiponectin in breast cancer patients. Mehmet Karaduman; Ahmet Ozet; Ali Sengul; Ugur Musabak; Melih Alomeroglu // Medical Oncology;Dec2007, Vol. 24 Issue 4, p361 

    Abstract Background  Adiponectin is a new adipocyte-secreted protein and associated with insulin-resistant status, such as type 2 diabetes mellitus and obesity. The inverse correlation between serum adiponectin levels and breast cancer risk was recently documented. On the other hand, the...

  • Relationships between TIMP-1, CAIX, and clinical outcomes in Egyptian breast cancer. Aly, Rabab; Elghannam, Doaa; Yousef, Ansaf // Comparative Clinical Pathology;Jul2014, Vol. 23 Issue 4, p907 

    Serum levels of carbonic anhydrase IX (CAIX) and the tissue inhibitor of metalloproteinase 1 (TIMP-1) have been demonstrated to be associated with clinical outcomes. Elevated TIMP-1 levels have been associated with a poor prognosis of breast cancer. Therefore, this study was performed to explore...

  • Correlation of Tissue Inhibitor of Metalloproteinase-2 with Proliferative Activity and Patients’ Survival in Breast Cancer. Nakopoulou, Lydia; Katsarou, Sophia; Giannopoulou, Joanna; Alexandrou, Paraskevi; Tsirmpa, Joanna; Panayotopoulou, Effie; Mavrommatis, Johnny; Keramopoulos, Antonios // Modern Pathology;Jan2002, Vol. 15 Issue 1, p26 

    Tissue inhibitors of metalloproteinases (TIMPs) are endogenous regulators of matrix metalloproteinases (MMPs). They are believed to possess several distinct cellular functions, particularly the contradictory activities of inhibiting MMPs and promoting tumor cell growth. Immunohistochemistry was...

  • Matrix metalloproteinase expression patterns in luminal A type breast carcinomas. Decock, J.; Hendrickx, W.; Drijkoningen, M.; Wildiers, H.; Neven, P.; Smeets, A.; Paridaens, R. // Disease Markers;2007, Vol. 23 Issue 3, p189 

    Objective: Aberrant expression of individual matrix metalloproteinases has been associated with poor prognosis in various human carcinomas. The current study aimed at defining an RNA expression profile of various MMPs in breast cancer and correlating their expression with clinicopathological...

  • Increased serum level of membrane type 1-matrix metalloproteinase (MT1-MMP/MMP-14) in patients with breast cancer. Laudański, P.; Świątecka, J.; Kozłowski, L.; Leśniewska, M.; Wojtukiewicz, M.; Wołczyński, S. // Folia Histochemica et Cytobiologica;2010, Vol. 48 Issue 1, p101 

    Different types of matrix metalloproteinases, including membrane type 1 matrix metalloproteinase (MT1-MMP/MMP-14) can be easily detected in biological fluids and therefore may be contemplated as putative tumor markers. Although increased activity of MT1-MMP/MMP-14 have already been found in...

  • Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.  // Breast Cancer Research;2011, Vol. 13 Issue 4, p2916 

    The article focuses on the research to analyze the serum tissue inhibitor of metalloproteinase 1 and arbonic anhydrase IX related to circulating tumor cells in metastatic breast cancer patients. It states that tissue inhibitor of metalloproteinase 1 (TIMP-1) is important in angiogenesis,...

  • Exogenous coenzyme Q10 modulates MMP-2 activity in MCF-7 cell line as a breast cancer cellular model. Bahar, Massih; Khaghani, Shahnaz; Pasalar, Parvin; Paknejad, Maliheh; Khorramizadeh, Mohammad Reza; Mirmiranpour, Hossein; Nejad, Siavash Gerayesh // Nutrition Journal;2010, Vol. 9, p62 

    Background/Aims: Matrix Metalloproteinases 2 is a key molecule in cellular invasion and metastasis. Mitochondrial ROS has been established as a mediator of MMP activity. Coenzyme Q10 contributes to intracellular ROS regulation. Coenzyme Q10 beneficial effects on cancer are still in controversy...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics